دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Health Status After Transcatheter Tricuspid-Valve Repair in Patients With Severe Tricuspid Regurgitation
Suzanne V. Arnold, MD, MHA, a Scott Goates, P HD, MBA, b Paul Sorajja, MD,c David H. Adams, MD, d Ralph Stephan von Bardeleben, MD,e Samir R. Kapadia, MD,f David J. Cohen, MD, MSC ,g,h on behalf of the TRILUMINATE Pivotal Trial Investigators
doi : 10.1016/j.jacc.2023.10.008
Volume 83, Issue 1, 2–9 January 2024, Pages 1-13
Health Benefits of Transcatheter Tricuspid Valve Repair: Is it Enough to Simply Feel Better?∗
Wayne B. Batchelor, MD, MHS, Abbas Emaminia, MD, Matthew W. Sherwood, MD, MHS
doi : 10.1016/j.jacc.2023.11.010
Volume 83, Issue 1, 2–9 January 2024, Pages 14-16
Clopidogrel vs Aspirin Monotherapy Beyond 1 Year After Percutaneous Coronary Intervention
Hirotoshi Watanabe, MD, a Takeshi Morimoto, MD, b Masahiro Natsuaki, MD, c Ko Yamamoto, MD,d Yuki Obayashi, MD,e Ryusuke Nishikawa, MD, e Kenji Ando, MD, d Koh Ono, MD,e Kazushige Kadota, MD, f Satoru Suwa, MD, g Itsuro Morishima, MD,h Ruka Yoshida, MD,i Yoshiki Hata, MD,j Masaharu Akao, MD,k Masahiro Yagi, MD, l Nobuhiro Suematsu, MD, m Yoshihiro Morino, MD, n Takafumi Yokomatsu, MD, o Itaru Takamisawa, MD, p Toshiyuki Noda, MD,q Masayuki Doi, MD,r Hideki Okayama, MD, s Yuichi Nakamura, MD, t Kiyoshi Hibi, MD,u Hiroki Sakamoto, MD, v Teruo Noguchi, MD, w Takeshi Kimura, MD, a on behalf of the STOPDAPT-2 Investigators
doi : 10.1016/j.jacc.2023.10.013
Volume 83, Issue 1, 2–9 January 2024, Pages 17-31
Clopidogrel for Long-Term Secondary Prevention After Coronary Artery Stenting∗
Anne Bellemain-Appaix, MD, a,b Gilles Montalescot, MD, PHD b
doi : 10.1016/j.jacc.2023.11.004
Volume 83, Issue 1, 2–9 January 2024, Pages 32-34
Contemporary Management and Outcomes of Patients With High-Risk Pulmonary Embolism
Taisei Kobayashi, MD,a,b Steven Pugliese, MD, c Sanjum S. Sethi, MD, MPH, d Sahil A. Parikh, MD,d Joshua Goldberg, MD,e Fahad Alkhafan, MD, MPH,f Clara Vitarello, MPH,f Kenneth Rosenfield, MD, g Robert Lookstein, MD,h Brent Keeling, MD, i Andrew Klein, MD, j C. Michael Gibson, MS, MD, f,k Lauren Glassmoyer, MD, a Sameer Khandhar, MD, a Eric Secemsky, MD, k Jay Giri, MD, MPH
doi : 10.1016/j.jacc.2023.10.026
Volume 83, Issue 1, 2–9 January 2024, Pages 35-43
High-Risk Acute Pulmonary Embolism: Where Do We Go From Here?∗
Behnam N. Tehrani, MD, a Wayne B. Batchelor, MD, MHS, a David Spinosa, MDa,b
doi : 10.1016/j.jacc.2023.11.001
Volume 83, Issue 1, 2–9 January 2024, Pages 44-46
Lung-to-Heart Nano-in-Micro Peptide Promotes Cardiac Recovery in a Pig Model of Chronic Heart Failure
Alessio Alogna, MD, PHD, a,b,c Leonhard Berboth, MD,a Alessandro Faragli, MD,a Jens ?tv?s, D VM,a Francesco Paolo lo Muzio, P HD, a Vittoria di Mauro, PH D, d,e Jessica Modica, PHD, d,e Eride Quarta, P HD, f,g Lukas Semmler, MD,a Peter Maximilian Dei?ler, MD, a Yannic Wanja Berger, MS C, P HD, a Khai Liem Tran, MD,a Beatrice de Marchi, PHD, h Gianluigi Longinotti-Buitoni, PH D, h Lorenzo Degli Esposti, P HD, i Etienne Guillot, PHD, j Didier Bazile, P HD, j Michele Iafisco, PH D, i Alessandro Dotti, PH D, k Marie-Louise Bang, PHD, d,e Claudio de Luca, MBA, PH D, l Christina Brandenberger, P HD, m,n Louise Benazzi, P HD, o Dario di Silvestre, P HD, o Antonella de Palma, PH D, o Uwe Prime?nig, MD, PHD, a,b,c Felix Hohendanner, MD, PH D, a,b,c Simone Perna, PH D, p Francesca Buttini, PH D, f Paolo Colombo, PH D, f,g Christian Mühlfeld, MD, PH D, m,q Paul Steendijk, PH D, r Pierluigi Mauri, PHD, o Carsten Tsch?pe, MD,a Barry Borlaug, MD,s Burkert M. Pieske, MD, a,b,c Philipp Attanasio, MD, P HD, t Heiner Post, MD, a Frank R. Heinzel, MD, P HD, a,c Daniele Catalucci, P HD
doi : 10.1016/j.jacc.2023.10.029
Volume 83, Issue 1, 2–9 January 2024, Pages 47-59
Inhalable Therapies for the Heart: Take the “Lung� Way Home?∗
Jean-Sébastien Hulot, MD, P HD, a,b Christian Kupatt, MD
doi : 10.1016/j.jacc.2023.10.028
Volume 83, Issue 1, 2–9 January 2024, Pages 60-62
Novel Techniques in Imaging Congenital Heart Disease: JACC Scientific Statement
Ritu Sachdeva, MBBS, a Aimee K. Armstrong, MD, b Rima Arnaout, MD,c Lars Grosse-Wortmann, MD, d B. Kelly Han, MD, e Luc Mertens, MD, PH D, f Ryan A. Moore, MD, MSC ,g Laura J. Olivieri, MD,h Anitha Parthiban, MBBS,i Andrew J. Powell, MD
doi : 10.1016/j.jacc.2023.10.025
Volume 83, Issue 1, 2–9 January 2024, Pages 63-81
Antithrombotic Therapy for Patients Undergoing Cardiac Electrophysiological and Interventional Procedures: JACC State-of-the-Art Review
Luigi Di Biase, MD, P HD, a Dhanunjaya J. Lakkireddy, MD,b Jacopo Marazzato, MD, PH D, a Alejandro Velasco, MD,a Juan Carlos Diaz, MD,a Rachita Navara, MD, c Jonathan Chrispin, MD, d Bharath Rajagopalan, MD, e Andrea Natale, MD,f Sanghamitra Mohanty, MD,f Xiaodong Zhang, MD, PH D, a Domenico Della Rocca, MD,f Aarti Dalal, MD,g Ki Park, MD,h Jose Wiley, MD,i Wayne Batchelor, MD, j Jim W. Cheung, MD,k George Dangas, MD, P HD, i Roxana Mehran, MD, l Jorge Romero, MD, a on the behalf of the ACC Electrophysiology and Interventional Councils
doi : 10.1016/j.jacc.2023.09.831
Volume 83, Issue 1, 2–9 January 2024, Pages 82-108
2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
doi : 10.1016/j.jacc.2023.08.017
Volume 83, Issue 1, 2–9 January 2024, Pages 109-279
2023 Atrial Fibrillation Guideline-at-a-Glance
doi : 10.1016/j.jacc.2023.10.021
Volume 83, Issue 1, 2–9 January 2024, Pages 280-284
Declining Cardiology Board Pass Rates
Anis John Kadado, MD, Abdullah Pervaiz, MD, Quinn Pack, MD, MS
doi : 10.1016/j.jacc.2023.09.834
Volume 83, Issue 1, 2–9 January 2024, Pages 285-289
RESPONSE: Declining Cardiology Board Pass Rates: The Lingering Effects of COVID?
Jeffrey T. Kuvin, MD
doi : 10.1016/j.jacc.2023.09.837
Volume 83, Issue 1, 2–9 January 2024, Pages 288-289
Aspirin vs P2Y12 Inhibitors: A Few Questions Unanswered
Mostafa Reda Mostafa, MDa Claudine Abdou, RPH, MSb Kirolos Barssoum, MDc Hani Jneid, MD
doi : 10.1016/j.jacc.2023.09.832
Volume 83, Issue 1, 2–9 January 2024, Page e7
Clinically Significant Differences Between P2Y12 Inhibitor Monotherapy and Aspirin Monotherapy Have Yet to Be Demonstrated
*Eric R. Bates, MD
doi : 10.1016/j.jacc.2023.09.833
Volume 83, Issue 1, 2–9 January 2024, Pages e9-e10
Reply: Unconvinced by Data or Resistance to Change?
Felice Gragnano, MD, PhDa Paolo Calabr?, MD, PhDa Roxana Mehran, MDb *Marco Valgimigli, MD, PhD c,d on behalf of the PANTHER Collaboration
doi : 10.1016/j.jacc.2023.10.027
Volume 83, Issue 1, 2–9 January 2024, Pages e11-e12
